Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants priority review to Roche's filing for Tecentriq in triple-negative breast cancer

firstwordpharmaNovember 14, 2018

Tag: Abraxane , Top Story , Tecentriq

PharmaSources Customer Service